Genomic and functional characterization of a novel temperate Coventryvirus phage infecting Staphylococcus pseudintermedius Authors: Patoo Withatanung, Sukanya Apiratwarrasakul, Pathomporn Sresuwadjarey, Nathita Phumthanakorn, Varintip Lerdsittikul Published: 2025 ABSTRACT AbstractThe rise of methicillin-resistant Staphylococcus pseudintermedius (MRSP), a multidrug-resistant zoonotic pathogen with strong biofilm-forming ability, highlights the urgent need for alternative therapies. Here, we report the isolation and comprehensive characterization of vB_SpsS_VL4 (VL4), a novel temperate phage obtained from sewage using a clinical MRSP isolate. VL4 genome (39,788 bp) contains 68 open reading frames (ORFs) with no virulence, resistance, or toxin genes and encodes lysis proteins with Cysteine, Histidine-dependent Amidohydrolase/Peptidase (CHAP) domains. Genomic and phylogenetic analyses classified VL4 as a new species within the Coventryvirus genus. Despite its temperate nature, VL4 demonstrated efficient replication (latent period 50 min; burst size 56 PFU per cell), remained viable at neutral pH and temperatures up to 37 °C, and significantly suppressed the host bacterial growth. Among 31 S. pseudintermedius clinical isolates, 27 (87%) strains were susceptible to VL4, while no activity was detected against Staphylococcus aureus. Moreover, VL4 inhibited biofilm formation and partially degraded mature MRSP biofilms. Collectively, these findings identify VL4 as a promising Coventryvirus phage with potential for future engineering and therapeutic development against difficult-to-treat MRSP infections.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-32942-7.Keywords: Bacteriophage, Dog, Lysogeny, MRSP, Staphylococcus pseudintermedius, Temperate phageSubject terms: Microbiology, Molecular biology Introduction Staphylococcus pseudintermedius, a coagulase-positive member of the Staphylococcus intermedius group (SIG), is an opportunistic pathogen predominantly affects dogs and other companion animals1,2. It is frequently associated with skin infections (pyoderma), ear infection (otitis externa), post-surgical complications, and urinary tract infections3. In recent years, the emergence and global dissemination of methicillin-resistant S. pseudintermedius (MRSP) have posed a growing challenge in veterinary medicine. These strains are resistant to all β-lactams and often exhibit multidrug resistance4–6, which severely limits therapeutic options. Global epidemiological studies of MRSP have revealed high genetic diversity, with varying frequencies of MRSP clones reported across countries and continents7. In Thailand, MRSP belonging to diverse Sequence types (STs) have been reported in canine and feline isolates, with MRSP ST45 identified as the predominant clone8,9. These isolates display multidrug resistance and carry numerous resistance genes, similar to those described in other geographical regions. In addition to antimicrobial resistance, biofilm formation plays a crucial role in the persistence and virulence of S. pseudintermedius. Biofilms are structured microbial communities embedded in a self-produced extracellular matrix that adheres to both biotic and abiotic surfaces, including tissues, surgical tools, and indwelling devices10. Within biofilm, MRSP displays increased tolerance to antibiotics and evades host immunity, contributing to chronic and recurrent infections11,12. Biofilms also facilitate horizontal gene transfer, enhance environmental survival, and enable bacterial dissemination through fragment detachment13. The zoonotic potential of MRSP adds another layer of concern, with human infections increasingly reported, particularly in individuals with close contact to infected animals or those with compromised immune systems14,15. Collectively, the combination of multidrug resistance, biofilm-associated resilience, and zoonotic risk underscores the urgent need for alternative therapeutic strategies targeting both planktonic and biofilm-associated bacterial populations. Bacteriophage (phage) therapy utilizes the ability of phages to specifically infect and lyse bacteria, offers a targeted alternative to antibiotics with minimal impact on the host microbiota16. Phages are broadly categorized as lytic (virulent) or temperate (lysogenic). Lytic phages immediately destroy their bacterial hosts, making them ideal candidates for therapeutic use17. In contrast, temperate phages integrate into the bacterial genome and may remain dormant before initiating the lytic cycle18. Due to their potential to mediate horizontal gene transfer and promote bacterial virulence or resistance, temperate phages have traditionally been excluded from therapeutic applications19–21. However, recent advances in synthetic biology have enabled the engineering of temperate phages to eliminate lysogeny, enhance lytic activity, and expand host range, as demonstrated in Enterococcus faecalis22,23. Furthermore, combining temperate phages with antibiotics has shown synergistic effects in vitro24, and engineered temperate phages have also been adapted for diagnostic applications. These developments highlight the underexplored potential of temperate phages in both therapeutic and research contexts25,26. Although three virulent phages targeting S. pseudintermedius have recently been identified27, studies on temperate phages remain limited28–30. Several temperate S. pseudintermedius phages have shown promise in combating multidrug-resistant strains and disrupting MRSP-associated biofilms, suggesting untapped therapeutic potential28–30. However, genomic data for these phages remain scarce in public repositories such as NCBI and PhageAI31, hindering efforts to assess their genetic diversity and screen for virulence or resistance determinants critical to their safety and efficacy. Addressing this data gap is essential. Continued isolation and characterization of temperate phages will not only enrich the current genomic landscape but also help identify candidates with broad host range and anti-biofilm capabilities. Furthermore, such foundational knowledge is crucial for guiding future genetic engineering efforts aimed at enhancing the therapeutic utility of temperate phages. In the present study, we describe the isolation and comprehensive characterization of a temperate Staphylococcus phage, vB_SpsS_VL4 (VL4), infecting S. pseudintermedius from sewage samples. VL4 was analyzed in terms of morphology, host range, bacteriolytic activity, genomic features, and phylogenetic relationship within the Coventryvirus genus. VL4 exhibited dose-dependent inhibition of biofilm formation and partial disruption of mature MRSP biofilms. These findings expand the current repertoire of temperate S. pseudintermedius phages and highlight their potential as foundational models for future genetic engineering and therapeutic development against MRSP infections. Results S. pseudintermedius clinical isolates, antibiotic resistance and biofilm formation Thirty-one clinical S. pseudintermedius isolates, used in this study, were tested for antimicrobial susceptibility. The highest resistance rate to benzylpenicillin (96.77%), followed by oxacillin (80.64%), enrofloxacin and marbofloxacin (both 74.19%). Additional resistance rates were observed for trimethoprim/sulfamethoxazole (70.96%), pradofloxacin (70.96%), clindamycin (64.51%), erythromycin (61.29%), chloramphenicol (45.16%), doxycycline (41.93%), and gentamicin (12.90%). In contrast, lower resistance rates were noted for minocycline (6.45%), nitrofurantoin (3.22%), while no resistance was detected for amikacin and florfenicol. Notably, 80.64% of the isolates exhibited multidrug resistance, as shown in Supplementary Fig. S1 and Supplementary Table S1. All S. pseudintermedius isolates demonstrated biofilm-forming ability with various adherence levels. The majority (72.4%) were strong biofilm producers, while 27.6% and 6.9% were moderate and weak producers, respectively. Among methicillin-resistant isolates (MRSP, n = 24), 70.8% were strong and 29.2% moderate biofilm formers. In contrast, methicillin-susceptible isolates (MSSP, n = 7) showed greater variability, with 28.6% strong, 42.9% moderate, and 28.6% weak biofilm production (Supplementary Fig. S2). Characterization of MRSP strain HVL4: a representative host for isolating phages targeting high-risk MRSP To identify a suitable host for phage isolation, S. pseudintermedius clinical isolates were screened for prophage induction using mitomycin C. This approach is commonly used to assess prophage inducibility since inducible prophages can lyse their hosts and interfere with exogenous phage enrichment32,33. Non-inducible strains are therefore preferred hosts because they minimize the confounding release of resident prophages during enrichment. Among them, only MRSP-HVL4 resisted mitomycin C-induced lysis (Supplementary Table S2). Despite the lack of inducibility, whole genome sequencing of MRSP-HVL4 revealed an integrated prophage, vB_SpsS_QT1 (NC_048192.1), classified under the genus Fibralongavirus (Supplementary Fig. S3). This finding suggests that the prophage is non-inducible or requires specific triggers, but the absence of spontaneous induction suggests that MRSP strain HVL4 may serve as a suitable host for phage isolation. Additionally, genomic analysis of MRSP-HVL4 identified multiple antimicrobial resistance genes, including mecA, blaZ, aph3-IIIa, ermB, aac(6’)-Ie-aph(2’’)-Ia, tet(W/N/W), sat-4, and catpC221 (Supplementary Table S3). Several virulence-associated genes were also detected, including the icaA, icaB, icaC, and icaD genes responsible for polysaccharide intercellular adhesin synthesis and biofilm formation, as well as genes involved in enzymatic activity, invasion, and toxin production (aur, hlyA, hlb, eta, and iap/cwhA). These findings indicate that MRSP-HVL4 possesses high pathogenic potential, reinforcing its relevance as a target strain for phage isolation. Multi-locus sequence typing (MLST) categorized MRSP-HVL4 as ST45, a prevalent lineage in Thailand, further supporting its use as a representative host for isolating phages targeting clinically relevant MRSP strains. Phage VL4: a member of the class Caudoviricetes A phage capable of infecting S. pseudintermedius isolate MRSP-HVL4, designated Staphylococcus phage VL4, was isolated from wastewater samples. On the bacterial lawns of MRSP-HVL4, VL4 formed round, turbid plaques with a bull’s-eye spot appearance, approximately 1 mm in diameter (Fig. 1a and b). Transmission electron microscope (TEM) examination revealed that phage VL4 has an icosahedral head (60 nm in diameter) and long, flexible, non-contractile tail (165 nm in length) (Fig. 1c). Phage VL4 was subsequently classified within the class Caudoviricetes. Morphological and genomic characterization of phage VL4 and its phylogenetic relationship within the Coventryvirus genus. (a) Representative bull’s-eye plaque morphology of VL4 on a lawn of methicillin-resistant S. pseudintermedius (MRSP) strain HVL4. (b) Close-up image of individual plaque formed by VL4. (c) Transmission electron micrograph of phage VL4 showing an icosahedral head and long non-contractile tail; stained with 2% (w/v) uranyl acetate. Scale bar = 200 nm. (d) Intergenomic similarity heatmap generated by VIRIDIC based on BLASTn, visualizing percent nucleotide identity, genome alignment fractions, and length ratios. VL4 (OP168678) is highlighted in red and shows highest identity (78.3%) with Staphylococcus phage SpT152 (KX827369). (e) Whole-genome-based phylogenetic tree constructed using VICTOR (GBDP method), illustrating the taxonomic placement of VL4 within the Coventryvirus genus. Genomic features such as family/genus affiliation, genome size, GC content, and coding density are indicated. Phage VL4 represents a novel member of the genus Coventryvirus Whole genome analysis revealed that phage VL4 possesses a complete double-stranded DNA genome of 39,788 bp with a GC content of 35.5%. To explore its taxonomic placement, the VL4 genome was analyzed using BLASTn (Megablast) against the NCBI non-redundant database following ICTV taxonomy guidelines34. Comparative genomic analysis placed VL4 within the Coventryvirus genus. BLASTn (Megablast) revealed up to 95.20% nucleotide identity over 68% of its genome with known Coventryvirus members, while VIRIDIC analysis confirmed its closest relationship to Staphylococcus phage SpT152 (78.3% identity), and the most distant to phage vB_SpsX-DS4 (54.4%) (Fig. 1d; Supplementary Table S4). To further clarify the taxonomic position of phage VL4 within the Coventryvirus genus, genome-based phylogeny was performed using VICTOR. The resulting tree placed VL4 in a distinct clade, meeting ICTV species demarcation criteria (< 95% nucleotide identity across the full genome; Fig. 1e). Proteomic analysis using ViPTree supported this placement, with VL4 clustering within Coventryvirus but forming a separate branch from its closest relatives, phages SpT152 and phiSP44-1 (Fig. 2a–b). Together, these findings confirm that VL4 represents a novel species within the genus Coventryvirus, under the class Caudoviricetes. Whole-proteome-based phylogenetic analysis of phage VL4 using ViPTree. (a) Circular proteomic tree illustrating the genome-wide relatedness of VL4 (OP168678; marked with a red star) to reference viral genomes in the NCBI RefSeq database, based on tBLASTx comparisons. Segment positions reflect evolutionary distances, while color coding represents virus families or host classifications. (b) Rectangular phylogenetic tree generated from 5,633 viral genomes. VL4 clusters within the Herelleviridae family, subfamily Twortvirinae, and groups closely with Staphylococcus phage SpT152, supporting its placement within the Coventryvirus genus. Functional genomic characterization of phage VL4 PhageTerm analysis was used to determine VL4’s genome packaging strategy. Although no definitive class or type was assigned (Class [–], Type [–]), the results indicated random termini and a permuted genome with terminal redundancy, features consistent with a headful (pac-type) packaging mechanism. Li’s method further supported this interpretation (Supplementary Fig. S4). These findings indicate that VL4 has a linear, circularly permuted, and terminally redundant genome, typical of headful-packaging phages. Genome annotation of phage VL4 identified 68 predicted ORFs (Supplementary Table S5 and Fig. 3a), grouped into six functional categories: (1) DNA packaging, (2) head and tail assembly, (3) DNA replication and metabolism, (4) host lysis, (5) lysogeny, and (6) hypothetical proteins of unknown function. No tRNA genes, antimicrobial resistance genes, virulence factors, or putative toxins were detected, supporting the phage’s therapeutic safety profile. Notably, genes encoding host lysis proteins were identified, including a bifunctional autolysin (EC 3.5.1.28 and EC 3.2.1.96; LytD, COG4193), a lysin (EC 3.5.1.28), and a holin. These lytic enzymes carrying CHAP domains responsible for peptidoglycan degradation, facilitating host lysis during infection35. DeepTMHMM analysis was performed to identify transmembrane domains (TMDs) in putative proteins, aiming to reveal membrane-associated components potentially involved in phage structure and function. The analysis predicted TMDs in five putative proteins (ORFs: 16, 22, 24, 39, and 67). A single TMD was detected in ORFs 22 and 67, both of which were predicted to encode hypothetical proteins. In contrast, two TMDs were identified in a tail protein (ORF 16), a putative holin (ORF 24), and another hypothetical protein (ORF 39) (see Supplementary Fig. S5 and Table S5). Genomic organization and comparative analysis of phage VL4. (a) Genome map of VL4 showing 68 ORFs. Color-coded by functional category: DNA packaging (green), head and tail assembly (yellow), host lysis (red), lysogeny (blue), DNA replication/metabolism (pink), and hypothetical/unknown function (grey). (b) Synteny analysis of phage VL4 compared with its closest relatives, Staphylococcus phages SP276 and SpT152. ORFs are shown as arrows and colored by functional category (structural, lysis, integrase, accessory, and terminase). Homologous genes are linked by grey shading, representing amino acid identity (0–100%). Genes showing sequence variation among the phages, including integrase (Int), terminase small (G1) and large (G2) subunits, and accessory genes (G3–G8), are indicated. Scale bar represents 2.5 kb. Genomic comparison of phage VL4 with related Staphylococcus phages BLASTn analysis indicated that VL4 is most closely related to phage SP276, followed by phage SpT152, supporting its placement as a distinct member of the Coventryvirus lineage. Genome synteny comparison with SP276 and SpT152 (Fig. 3b) revealed a conserved backbone in structural and lysis modules. Several loci displayed sequence divergence or unique gene content. The terminase small and large subunits (G1 and G2) differed from their homologs, which may reflect variation in DNA packaging specificity, while the tail length tape measure protein (G3) exhibited minor sequence differences possibly linked to structural adaptation. Phage VL4 also encodes accessory genes absent in its close relatives, including an HNH homing endonuclease (G4), a RusA family resolvase (G6), a dUTPase (G7), and a class I SAM-dependent methyltransferase (G8), together with several hypothetical proteins of unknown function. These genomic distinctions, together with the conserved core organization, suggest that VL4 is genetically distinct from previously characterized Staphylococcus phages and represents a novel member within the Coventryvirus lineage. Integration capability and lysogeny of phage VL4 Genes associated with lysogeny were identified in the VL4 genome, including an integrase, a repressor, and an antirepressor, which are essential for genome integration, maintenance of lysogeny, and induction of the lytic cycle, respectively36. In addition, predicted bacterial attachment sites, attL and attR (TTTCGAAAGTGA) flanking the integrase gene further support the use of a site-specific recombination mechanism during lysogeny37 (Supplementary Table S5). The presence of lysogeny-associated genes and flanking att sites suggests VL4’s capacity for genome integration. This was supported by PhageAI, which predicted a temperate lifestyle with 99.84% confidence. To experimentally validate lysogeny, phage-resistant colonies derived from wild-type MRSP-HVL4 were screened by PCR targeting the major capsid gene, which detected phage VL4 DNA in two of four colonies (Fig. 4a), and the signal persisted through five serial subcultures (Fig. 4b), confirming stable lysogeny. In contrast, the remaining two phage-resistant colonies were PCR-negative for the major capsid gene but remained refractory to reinfection, suggesting resistance via non-lysogenic mechanisms. To investigate this possibility, the genome of MRSP strain HVL4 was analyzed using Padloc38 and CRISPRDetect39. No CRISPR-Cas loci were identified; however, several other defense systems were detected, including type II restriction–modification (RM) systems, Gabija, CBASS type IIs, Rosmer toxin–antitoxin, and prokaryotic defense clusters (Supplementary Table S6). The presence of these predicted systems may account for the observed phage resistance in the absence of prophage integration. Confirmation of lysogenization of phage VL4 in MRSP strain HVL4. (a) PCR detection of the VL4 major capsid protein gene (223 bp) in phage-resistant MRSP colonies MT1 and MT4, confirming lysogenization. WT: wild-type MRSP-HVL4; (+): positive control (VL4 DNA); (–): negative control (no template). (b) PCR amplification of the same gene in MT1 and MT4 after five consecutive subcultures (R1-R5), demonstrating stable maintenance of VL4 in the host genome. Original gel images are provided in Supplementary Fig. S6. Biological characteristics of phage VL4 VL4 infection dynamics were characterized using MRSP-HVL4. The optimal MOI was 0.01, yielding the highest phage titer (Fig. 5a). Adsorption assays showed that over 80% of particles bound to host cells within 10 min at 37 °C (Fig. 5b). One-step growth analysis indicated a latent period of ~ 50 min and a burst size of 56 PFU/cell (Fig. 5c), demonstrating efficient replication in vitro. Phage stability tests showed that phage VL4 remained stable at neutral pH (7), but its infectivity declined under acidic (pH 3–6) and mildly alkaline (pH 8) conditions, with complete inactivation at pH 1, 2, 9, and 10 (P < 0.0001; Fig. 5d). It also retained activity after 1 h at 4 °C, 25 °C, and 37 °C, but viability dropped significantly at 40 °C and 50 °C, and was lost above 60 °C (P < 0.0001; Fig. 5e). Thus, VL4 is stable under short-term physiological conditions, supporting its suitability for laboratory applications. In vitro biological characterization of phage VL4 using MRSP strain HVL4 as the host. (a) Optimal MOI determination for maximal phage yield. (b) Adsorption kinetics showing the percentage of phage particles adsorbed over time. (c) One-step growth curve assay, illustrating the latent period and burst size of phage VL4. (d) Stability of VL4 after 1-h incubation at various pH levels (1–10) in LB medium. Significant loss of activity was observed under acidic and alkaline conditions. (e) Thermal stability of VL4 after 1-h incubation at temperatures ranging from 4 °C to 70 °C. Phage viability declined significantly at ≥ 40 °C. Data are shown as mean ± SD from three independent experiments. Statistical significance was assessed by one-way ANOVA with Dunnett’s post hoc test (****P < 0.0001). Phage host range and relative efficiency of plating (EOP) The host range of phage VL4 was examined against 31 clinical S. pseudintermedius isolates and 10 S. aureus isolates. Phage VL4 produced clear or turbid plaques on 27 of 31 S. pseudintermedius isolates (87%), while no lytic activity was observed against S. aureus (Table 1). To further characterize its infectivity, the EOP was determined using MRSP-HVL4 as the reference strain. Among the susceptible isolates, one exhibited high EOP, three medium, and the remaining low EOP values (Table 1). Four strains that were negative in the VL4 plaque assay were PCR-positive for the VL4 capsid gene prior to infection, indicating the presence of a VL4-like prophage in their genomes (Supplementary Fig. S7). Table 1Antibiotic susceptibility and host range of phage VL4 against clinical isolates of S. pseudintermedius and S. aureus.Bacterial speciesStrainsSourcesAntibiotic resistancePhage VL4 KillingPlaque formationEOP S. pseudintermedius MRSP-HVL4Wound/DogBENPEN, OX, ENR, MAR, PRA, E, DA, MNO, C+1High (host)MRSP-BA01Wound/DogBENPEN, OX, ENR, MAR, PRA, E, C, SXT+0.053 ± 0.006LowMRSP-BA02Urine/CatBENPEN, OX, ENR, MAR, PRA, E, DO, NIT, C, SXT+0.016 ± 0.005LowMRSP-BA03Wound/DogBENPEN, OX, ENR, MAR, PRA, E, DA, SXT+0.003 ± 0.002LowMRSP-BA04Wound/DogBENPEN, OX, ENR, MAR, PRA, E, DA, DO, C, SXT+0.32 ± 0.08MediumMRSP-BA05Wound/DogBENPEN, OX, SXT+0.22 ± 0.02LowMRSP-BA06Urine/CatBENPEN, OX, ENR, MAR, PRA, E, DA, C, SXT+0.10 ± 0.01LowMRSP-BA07Wound/CatBENPEN, OX, ENR, MAR, PRA, E, DA, DO, C+0.016 ± 0.008LowMRSP-BA08Wound/DogBENPEN, OX, ENR, MAR, PRA, DA, DO, C+0.006 ± 0.002LowMRSP-BA09Wound/DogBENPEN, OX, ENR, MAR, PRA, E, DA, SXT+0.013 ± 0.005LowMRSP-BA10Body fluid/DogBENPEN, OX, DA, SXT−NDMRSP-BA11Urine/DogBENPEN, OX, CN, ENR, MAR, PRA, E, DA, DO, SXT−NDMRSP-BA12Wound/DogBENPEN, OX, ENR, MAR, PRA, DO, SXT+0.007 ± 0.004LowMRSP-BA13Ear/DogBENPEN, OX, ENR, MAR, PRA, E, DA, DO, C, SXT+0.018 ± 0.010LowMRSP-BA14Wound/DogBENPEN, OX, ENR, MAR, PRA, E, DO, C, SXT+0.036 ± 0.013Low S. pseudintermedius MRSP-BA15Urine/DogBENPEN, OX, ENR, MAR, PRA, E, DO, C, SXT+0.14 ± 0.06LowMRSP-BA16Urine/DogBENPEN, OX, DA, SXT+0.004 ± 0.004LowMRSP-BA17Urine/DogBENPEN, OX, ENR, MAR, SXT−NDMRSP-BA18Wound/DogBENPEN, OX, ENR, MAR, PRA E, DA, C, SXT−NDMRSP-BA19Wound/DogBENPEN, OX, ENR, MAR, PRA E, DA, DO, SXT+0.004 ± 0.004LowMRSP-BA20Wound/DogBENPEN, OX, DA, SXT+0.016 ± 0.003LowMRSP-BA21Urine/DogBENPEN, OX, ENR, MAR, PRA, DO, SXT+0.025 ± 0.005LowMRSP-BA22Wound/DogBENPEN, OX, CN, ENR, MAR, E, DA, DO, SXT+0.12 ± 0.04LowMRSP-BA23Wound/DogBENPEN, OX, CN, ENR, MAR, PRA, E, DA, MNO, C+0.0067 ± 0.0012LowMRSP-BA24Wound/DogBENPEN, OX, CN, ENR, MAR, PRA, E, DA, DO, SXT+0.16 ± 0.06LowMSSP-BA25Urine/DogBENPEN+0.027 ± 0.021LowMSSP-BA26Urine/DogBENPEN, PRA, DA+0.0133 ± 0.0006LowMSSP-BA27Urine/DogBENPEN, DA+0.012 ± 0.009LowMSSP-BA28Pus/DogBENPEN, ENR, MAR, PRA, E, C, SXT+0.43 ± 0.11MediumMSSP-BA29Pus/Dog+0.12 ± 0.05LowMSSP-BA30Urine/DogBENPEN, ENR, MAR, PRA, E, C+0.016 ± 0.004Low S. aureus MRSA-BA01Wound/CatBENPEN, OX, CN, ENR, MAR, PRA, DA, DO, MNO, SXT−NDMRSA-BA02Wound/CatBENPEN, OX, ENR, MAR, PRA, DA−ND S. aureus MRSA-BA03Wound/CatBENPEN, OX, ENR, MAR, PRA, E, DA−NDMRSA-BA04Urine/CatBENPEN, OX, ENR, MAR, PRA, DA, DO, MNO−NDMRSA-BA05Wound swab/CatBENPEN, OX, ENR, MAR, PRA, E, DA, DO, SXT−NDMRSA-BA06Urine/DogBENPEN, OX, ENR, MAR, PRA, DA, DO, MNO, SXT−NDMSSA-BA07Urine/CatBENPEN OX, ENR, MAR, PRA, DA, DO, MNO, SXT−NDMSSA-BA08Pus/CatBENPEN, ENR, MAR, E, C−NDMSSA-BA09Ear/DogBENPEN−NDMSSA-BA10Body fluid/DogBENPEN−ND“+” indicates phage susceptibility; “–” indicates resistance; ND , not determined; Efficiency of plating (EOP): high = 0.5–1.0, moderate = 0.2–0.5, low = 0.001–0.2BENPEN , benzylpenicillin; OX , oxacillin; CN , gentamicin; ENR , enrofloxacin; MAR , marbofloxacin; PRA , pradofloxacin; E , erythromycin; DA , clindamycin; DO , doxycycline; MNO , minocycline; NIT , nitrofurantoin; C , chloramphenicol; SXT , trimethoprim/sulfamethoxazole; Strain categories: MRSP , methicillin-resistant S. pseudintermedius; MSSP , methicillin-sensitive S. pseudintermedius; MRSA , methicillin-resistant S. aureus; MSSA , methicillin-sensitive S. aureus. Antibiotic susceptibility and host range of phage VL4 against clinical isolates of S. pseudintermedius and S. aureus. 1 High (host) 0.053 ± 0.006 Low 0.016 ± 0.005 Low 0.003 ± 0.002 Low 0.32 ± 0.08 Medium 0.22 ± 0.02 Low 0.10 ± 0.01 Low 0.016 ± 0.008 Low 0.006 ± 0.002 Low 0.013 ± 0.005 Low 0.007 ± 0.004 Low 0.018 ± 0.010 Low 0.036 ± 0.013 Low 0.14 ± 0.06 Low 0.004 ± 0.004 Low 0.004 ± 0.004 Low 0.016 ± 0.003 Low 0.025 ± 0.005 Low 0.12 ± 0.04 Low 0.0067 ± 0.0012 Low 0.16 ± 0.06 Low 0.027 ± 0.021 Low 0.0133 ± 0.0006 Low 0.012 ± 0.009 Low 0.43 ± 0.11 Medium 0.12 ± 0.05 Low 0.016 ± 0.004 Low “+” indicates phage susceptibility; “–” indicates resistance; ND , not determined; Efficiency of plating (EOP): high = 0.5–1.0, moderate = 0.2–0.5, low = 0.001–0.2 BENPEN , benzylpenicillin; OX , oxacillin; CN , gentamicin; ENR , enrofloxacin; MAR , marbofloxacin; PRA , pradofloxacin; E , erythromycin; DA , clindamycin; DO , doxycycline; MNO , minocycline; NIT , nitrofurantoin; C , chloramphenicol; SXT , trimethoprim/sulfamethoxazole; Strain categories: MRSP , methicillin-resistant S. pseudintermedius; MSSP , methicillin-sensitive S. pseudintermedius; MRSA , methicillin-resistant S. aureus; MSSA , methicillin-sensitive S. aureus. Bacteriolytic activity of phage VL4 against clinical isolates of S. pseudintermedius The bacteriolytic potential of phage VL4 was evaluated against four S. pseudintermedius clinical isolates (MRSP-HVL4, MRSP-BA04, MRSP-BA05, and MSSP-BA28) by monitoring bacterial growth over 16 h (Fig. 6a–d). These strains, obtained from canine soft tissue wounds or pus samples (Table 1), were chosen for their clinical relevance, distinct antibiotic resistance profiles (Table 1 and Supplementary Table S1), strong biofilm-forming capacity (Supplementary Fig. S2), and susceptibility to VL4 based on EOP values. Phage VL4 markedly reduced bacterial growth in the four tested strains relative to the untreated controls (Fig. 6a–d). Rapid lytic activity occurred during early exponential growth, resulting in a sharp optical density (OD) reduction within 4 h. At an MOI of 1, VL4 suppressed bacterial growth for 16 h, whereas cultures infected at an MOI of 0.1 showed partial regrowth after 8–10 h, indicating a dose-dependent effect. These results demonstrate that VL4 effectively infects and lyses multiple S. pseudintermedius isolates. Effect of phage VL4 on the growth of four clinical isolates of S. pseudintermedius. Bacterial strains (a) MRSP-HVL4, (b) MRSP-BA04, (c) MRSP-BA05, and (d) MSSP-BA28 were co-cultured with phage VL4 at MOIs of 0.1 and 1, and incubated at 37 °C. Bacterial growth was monitored by measuring OD600 over 16 h. Data represent the mean ± SD from three independent experiments. Bacterial cultures without phage served as controls. Phage VL4 inhibits and disrupts S. pseudintermedius biofilms The anti-biofilm activity of VL4 was evaluated against four strong biofilm-producing strains (MRSP-HVL4, MRSP-BA04, MRSP-BA05, and MSSP-BA28). During biofilm formation, co-incubation with VL4 at 107, 108 and 109 PFU/mL resulted in a dose-dependent decrease in biofilm biomass, with 70–90% inhibition at the highest concentration (Fig. 7a–d). Viable-cell counts confirmed this trend, showing ~ 0.3–1.5 log CFU/mL reductions relative to untreated controls (Fig. 7e–h). Phage VL4-mediated inhibition of biofilm formation in clinical isolates of S. pseudintermedius. Panels (a–d) show biofilm biomass quantified by crystal violet staining for strains (a) MRSP-HVL4, (b) MRSP-BA04, (c) MRSP-BA05, and (d) MSSP-BA28 after co-culture with phage VL4 at 107, 108, and 109 PFU/mL at 37 °C for 24 h. Representative wells beneath each bar illustrate the corresponding crystal-violet staining intensity. The original image is provided in Supplementary Fig. S8. Panels (e–h) present viable-cell counts from the same biofilms. Data represent the mean ± SD from three independent experiments. Statistical significance was determined using one-way ANOVA followed by Dunnett’s post hoc test (**P < 0.01). For pre-formed (24 h) biofilms, VL4 treatment at 108, 109, and 1010 PFU/mL for 24 h at 37 °C caused a significant decrease in biomass and viable cells at the higher concentrations (Fig. 8a–h). In contrast, treatment with less than 108 PFU/mL showed no significant reduction compared with the untreated control. The maximum reduction observed at 1010 PFU/mL reached approximately 0.9 log CFU/mL, indicating partial but notable disruption of mature biofilms. Taken together, these results indicate that VL4 can inhibit biofilm formation and partially disrupt established biofilms of S. pseudintermedius, supporting its potential as an anti-biofilm agent for further development. Phage VL4-mediated degradation of 24-h-old pre-formed biofilms in clinical isolates of S. pseudintermedius. Panels (a–d) show biofilm biomass quantified by crystal-violet staining for strains (a) MRSP-HVL4, (b) MRSP-BA04, (c) MRSP-BA05, and (d) MSSP-BA28 after treatment of pre-formed (24 h) biofilms with phage VL4 at 108, 109, and 1010 PFU/mL at 37 °C for 24 h. Representative wells beneath each bar illustrate the corresponding crystal violet staining intensity. The original image is provided in Supplementary Fig. S9. Panels (e–h) present viable cell counts from the same biofilms. Data represent the mean ± SD from three independent experiments. Statistical significance was determined using one-way ANOVA followed by Dunnett’s post hoc test (**P < 0.01). Discussion MRSP poses a significant challenge in veterinary medicine due to its multidrug resistance and zoonotic potential. Despite being the predominant Staphylococcal species in dogs, research on phages targeting S. pseudintermedius remains limited compared with studies on S. aureus. Most investigations have focused on genomic analyses of prophages or temperate isolates, with few reporting functional characterization or therapeutic evaluation. In this study, we identified and characterized phage VL4, a novel member of the Coventryvirus genus, thereby providing new insights into phages infecting S. pseudintermedius. Furthermore, considering MRSP’s zoonotic potential and its increasing detection in human infections, particularly among immunocompromised individuals and veterinary professionals, phages such as VL4 may also hold translational relevance within the One Health framework. Continued investigation of such cross-species pathogens is critical for integrated infectious disease management. Phage VL4 exhibited lytic activity against 87% of tested S. pseudintermedius clinical isolates, while showing no activity against S. aureus. This high degree of host specificity, typical of Coventryvirus phages, suggests that VL4 could serve as a potential candidate for targeted therapy with minimal impact on commensal microbiota. Despite uniform plaque formation across susceptible strains, variation in EOP indicates differences in replication performance, which may be influenced by receptor accessibility or bacterial defense mechanisms such as restriction–modification systems, CRISPR–Cas, or superinfection exclusion. Notably, four non-lysed strains were PCR-positive for the VL4 capsid gene prior to infection, suggesting the presence of a VL4-like prophage that confers superinfection immunity. The absence of plaques in these isolates therefore reflects prophage-mediated exclusion rather than a failure of VL4 to infect the host. Compared to previously described S. pseudintermedius-infecting phages such as pSp-J and pSp-S, which exhibited host coverage rates of 68% and 85%, respectively, and biofilm effects observed only at higher doses28, phage VL4 showed comparable or improved bactericidal activity, producing dose-dependent reductions in optical density over a 16-h period. To ensure that this promising activity is retained in practical applications, the environmental stability of VL4 was also evaluated. VL4 remained viable under physiological conditions for the duration of the assay (1 h), showing the highest infectivity at 37 °C and pH 7. However, its reduced activity under extreme pH conditions and elevated temperatures suggests that VL4 is sensitive to environmental stress, and that long-term stability and optimal storage parameters warrant further investigation. These findings are consistent with previous reports on other therapeutic phages, which often display peak activity within narrow environmental ranges28,40,41. Biofilm formation is a major virulence factor in Staphylococcal infections, playing a key role in chronicity, antibiotic resistance, and immune evasion. In MRSP, biofilm-associated infections are particularly challenging to treat using conventional antimicrobials10,42,43. VL4 demonstrated potent antibiofilm activity in both prevention and eradication assays. This dual functionality is rarely observed with conventional antibiotics13 and highlights VL4’s potential for treating biofilm-associated MRSP infections. The biofilm-disrupting activity of VL4 is likely driven by its lytic gene arsenal, which includes a bifunctional autolysin (LytD), a lysin, and a holin, each playing key roles in bacterial cell wall degradation. Both lytic enzymes contain CHAP domains, known to efficiently cleave peptidoglycan and promote bacterial lysis. Holins facilitate this process by forming pores in the cytoplasmic membrane, enabling endolysins to access the cell wall44. Together, these enzymes mediate bacterial lysis, which indirectly disrupts biofilm integrity by reducing the bacterial population within the matrix rather than directly degrading polysaccharide components such as the polysaccharide intercellular adhesin. In addition to its characterized lytic enzymes, no canonical depolymerase genes were identified in the genome of VL4, yet its ability to degrade established biofilms suggests the presence of uncharacterized enzymes or alternative mechanisms, such as reduced metabolic activity within the bacterial population during phage infection or indirect structural destabilization of the extracellular polymeric substances (EPS)45. These findings are consistent with prior reports on Coventryvirus phages such as pSp-J and pSp-S, which also demonstrated significant antibiofilm effects despite lacking known depolymerase genes28. These findings support the hypothesis that Coventryvirus phages may possess intrinsic or cryptic biofilm-disrupting capabilities, making them attractive candidates for treating biofilm-resilient bacterial infections. VL4’s dual activity against both planktonic and biofilm-associated MRSP cells further enhances its therapeutic relevance, especially in managing chronic or device-associated infections in companion animals. Beyond its functional efficacy, VL4 also possesses several genomic features that support its therapeutic potential. The 39.8 kb double-stranded DNA genome encodes 68 ORFs and notably lacks antimicrobial resistance genes, known virulence factors, and tRNA genes, key safety attributes for clinical phage applications46,47. These characteristics, together with the presence of potent lytic enzymes and demonstrated efficacy against both planktonic and biofilm-associated MRSP, reinforce the suitability of VL4 as a promising phage therapeutic candidate. The genome of VL4 also contains several distinctive features relative to closely related Staphylococcus phages, suggesting possible functional divergence. Variations in the terminase subunits may reflect differences in DNA packaging strategies or host specificity48,49. The presence of an HNH homing endonuclease likely contributes to DNA packaging during phage assembly50. VL4 also encodes accessory genes that could influence replication and host interactions, including a RusA endodeoxyribonuclease predicted to resolve Holliday junctions during DNA recombination and repair51, a dUTPase that may regulate cellular processes such as Staphylococcus pathogenicity islands induction and virulence gene mobilization52, and a class I SAM-dependent methyltransferase potentially involved in DNA or protein modification53. Taken together, these elements indicate that VL4 represents a genetically distinct Staphylococcus phage with a broadened functional repertoire relative to its close relatives. Although VL4 is a temperate phage, it exhibited robust lytic activity and strong antibiofilm effects, making it a promising therapeutic candidate against MRSP. However, as with all temperate phages, lysogenization results in the survival of infected cells that become immune to superinfection, allowing these lysogens to persist and potentially dominate the bacterial population after phage exposure. This selective advantage represents a key limitation of temperate phages for therapeutic use. In recent years, temperate phages have gained increasing attention for therapeutic use, with several strategies being explored to overcome their inherent limitations. Some temperate phages, such as MP22 and D3112 from Pseudomonas aeruginosa, have been shown to attenuate bacterial virulence without genetic modification54. Phage cocktails combining multiple phages have also demonstrated therapeutic efficacy; for instance, a four-phage formulation targeting Clostridioides difficile significantly reduced bacterial counts in fermentation systems55. Additionally, engineering approaches have enhanced the therapeutic performance of temperate phages, exemplified by phage ϕEf11, which was modified to inactivate its lysogeny module, thereby improving lytic capacity against E. faecalis23. VL4 harbors lysogeny-associated genes, including an integrase, repressor, and antirepressor, which enable site-specific genome integration and maintenance of lysogeny. These genetic elements represent potential targets for genetic modification to produce a strictly lytic phage, thereby eliminating the risk of lysogeny-associated gene transfer. Furthermore, VL4 utilizes a pac-type headful packaging mechanism with circularly permuted genomes, a system efficient for replication but also capable of mediating generalized transduction. Although the estimated frequency of transducing particles is low (~ 10⁻¹¹ PFU), this value was inferred from previous reports of Staphylococcus phages56 rather than determined experimentally for VL4. Nevertheless, this risk becomes more relevant at the high phage doses often used in therapeutic or biocontrol contexts56. In future work, this will be experimentally assessed using plasmid- or marker-based assays to quantify potential DNA transfer events. To mitigate these risks and fully exploit therapeutic potential of VL4, future studies should also focus on genome engineering to eliminate lysogeny functions and evaluate efficacy in vivo. Alternatively, VL4 could be incorporated into rationally designed phage cocktails to enhance coverage and reduce resistance emergence, offering a versatile strategy for managing multidrug-resistant MRSP infections in veterinary settings. The observation that two phage-resistant colonies lacked detectable VL4 DNA indicates that S. pseudintermedius can develop resistance through mechanisms other than lysogeny. Such resistance may arise from bacterial defense pathways that inhibit phage adsorption, DNA injection, or replication. Consistent with this, the presence of multiple predicted defense systems in MRSP-HVL4 suggests that intrinsic host immunity may play a role in the emergence of VL4-resistant variants. Despite these promising findings, several aspects warrant further investigation. All functional assays were performed in vitro, providing a controlled model for characterization but not fully reflecting the complexity of host–phage interactions in vivo. The anti-biofilm assays were static and in vitro, future studies using flow-cell or in vivo biofilm models will provide more physiologically relevant validation of VL4’s activity. The genetic and physiological bases of phage resistance and long-term coevolution between VL4 and its hosts also remain unclear. Moreover, the host range analysis did not include other coagulase-negative Staphylococcus species or genetically diverse MRSP isolates, which could clarify host specificity of VL4 and ecological range. Additionally, the transducing ability of VL4 was not experimentally assessed, which should be evaluated in future studies to ensure biosafety and exclude the possibility of resistance gene transfer. Although VL4 exhibited lytic and antibiofilm activities, its temperate nature implies a potential for lysogeny in susceptible hosts. For future therapeutic development, VL4 would therefore require genetic modification to remove lysogeny-associated genes and ensure a strictly lytic phenotype, thereby maintaining efficacy while eliminating superinfection immunity. In conclusion, phage VL4 displays essential features for therapeutic development, including lytic activity against S. pseudintermedius, genomic safety, and strong antibiofilm effects. Although its temperate nature presents challenges for direct use, genome engineering could yield a strictly lytic variant suitable for safe, effective control of multidrug-resistant, biofilm-associated MRSP infections in veterinary medicine. Materials and methods Ethics approval All experimental procedures involving S. pseudintermedius, S. aureus, and their corresponding phages were conducted in a Biosafety Level 2 (BSL-2) facility following standard laboratory biosafety guidelines and institutional standard operating procedures. The experimental protocols were reviewed and approved by the Institutional Biosafety Committee (IBC) of the Faculty of Veterinary Science, Mahidol University, under protocol number IBC/MUVS-B-012/2566. This study was conducted under exemption approval for the use of archived bacterial isolates from the Mahidol University–Institute Animal Care and Use Committee (FVS-MU-IACUC), with approved protocol numbers MUVS-2023-04-26 and MUVS-2023-06-39. No animal experimentation, anesthesia, or euthanasia was performed for this research. All bacterial isolates used were obtained from diagnostic specimens routinely submitted to the Microbiology Laboratory, Center for Veterinary Diagnosis, Faculty of Veterinary Science, Mahidol University. These samples originated from client-owned dogs and cats presented to the Veterinary Teaching Hospital for clinical care and were collected for treatment purposes by licensed veterinarians. As the study involved retrospective use of archived isolates without access to identifiable clinical or owner information, owner consent was not required under the exempt IACUC approval. Bacterial isolates, culture media, and antimicrobial susceptibility testing Thirty-one S. pseudintermedius and ten S. aureus clinical isolates were obtained from diagnostic samples from dogs and cats submitted to the Microbiology Laboratory, Center for Veterinary Diagnosis, Faculty of Veterinary Science, Mahidol University (Table 1). Species identification and antimicrobial susceptibility testing were performed using the VITEK 2 Compact system with disposable VITEK GP cards and VITEK AST-GP81 cards (bioMérieux, Marcy l’Etoile, France). MRSP was identified by oxacillin resistance, while methicillin-resistant S. aureus (MRSA) was confirmed through cefoxitin screening and oxacillin resistance. Minimum inhibitory concentrations (MICs) were interpreted according to Global CLSI-based, Global CLSI-based + Natural Resistance, and Natural Resistance guidelines, with the AES parameter set and therapeutic guidelines applied for categorical interpretation of the VITEK 2 antimicrobial susceptibility data. All isolates were cultured in Luria-Bertani (LB) broth or on 1.5% (w/v) LB agar (HiMedia, India) at 37 °C with shaking (120–150 rpm). For long-term storage, isolates were preserved at -80 °C in brain heart infusion broth (BHI; HiMedia) containing 15% (v/v) glycerol. Mitomycin C-induced phage induction for identifying prophage-free S. pseudintermedius strains To identify suitable S. pseudintermedius strains for phage isolation, 25 clinical isolates (Supplementary Table S1) were screened for inducible prophages using mitomycin C. Cultures were grown in LB broth at 37 °C with shaking until reaching mid-exponential phase (OD600 ≈ 0.4–0.6), followed by the addition of mitomycin C (final concentration 1 µg/mL; Sigma-Aldrich, USA). After 4 h of incubation, cultures were centrifuged (10,000 × g, 5 min), and supernatants were filtered through 0.45 μm membranes to remove residual bacteria. Filtered lysates were tested for phage activity using plaque assays on lawns of S. pseudintermedius. Plates were incubated at 37 °C for 24 h. Strains that failed to produce plaques were considered likely mitomycin C-resistance and thus suitable for phage isolation. The prophage-free status of selected strains was further confirmed by whole-genome sequencing. Isolation and purification of phage Phage isolation was conducted using the MRSP-HVL4 strain as the host. Sewage samples (200 mL) were collected from urban areas in Bangkok, Thailand, and filtered through 0.45 μm membrane filters (Millipore, USA). The filtrate was mixed with an equal volume of 2X LB broth (HiMedia, India) containing 1% (v/v) overnight culture of MRSP-HVL4 for enrichment, and incubated at 37 °C overnight. Following incubation, the culture was centrifuged, and the supernatant was filtered again (0.45 μm) to obtain phage-containing lysates. Spot assays were performed by applying 20 µL of the filtrate onto lawns of MRSP-HVL4, followed by incubation at 37 °C overnight. Zones of clearing indicated lytic phage activity. For purification, individual plaques were picked and resuspended in 1 mL SM buffer (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgSO₄, 0.01% gelatin; pH 7.4), then serially diluted and subjected to double agar overlay plaque assays57. This process was repeated at least four times to ensure clonality and purity of the isolated phage. Phage morphology Virion morphology was examined using transmission electron microscope (TEM) following the method as previously described58. Briefly, for negative staining, a highly purified phage suspension was gently loaded onto a surface of a 200-mesh copper grid before stained with 2% (w/v) uranyl acetate. The stained grids were then examined using a TEM (FEI, TECNAI T20) operated at 120 kV. Phage whole genome sequencing and bioinformatic analysis Genomic DNA of phage VL4 was treated with DNase I, RNase I (Thermo Scientific), and Proteinase K (Sigma-Aldrich), followed by extraction using the phenol: chloroform: isoamyl alcohol method59,60. Sequencing was performed using the Illumina platform (Macrogen Inc., South Korea) with the TruSeq Nano DNA Kit. High-quality reads were filtered and assembled de novo using SPAdes v3.13.061. Open reading frames (ORFs) were predicted using RAST62 and PHASTEST63, with functional annotations performed using BLASTp and NCBI’s Conserved Domain (CD) Search. Genome mapping was conducted with the SnapGene tool trial version 2025. Genome termini and packaging strategy were inferred using PhageTerm64, and lifestyle prediction was performed using PhageAI31. Antimicrobial resistance genes and variants were screened using the Resistance Gene Identifier (RGI) tool from the CARD database65. Virulence factors were assessed by BLASTp against the VFDB66, and tRNA genes were identified using tRNAscan-SE67. Transmembrane domains in predicted proteins were analyzed using DeepTMHMM68. For comparative genomic analysis, Clinker v0.0.2569 was utilized to investigate gene synteny and the conservation of functional modules across phage genomes. Anti-phage defense systems in bacteria were predicted using PADLOC v2.0.038 and CRISPRDetect39. Comparative genomic and phylogenetic analysis Comparative genomics of phage VL4 and related Staphylococcus phages was performed using the VIRIDIC platform70, to calculate intergenomic similarities. Phylogenetic relationships were inferred using the VICTOR workflow71, which generated a Genome-BLAST Distance Phylogeny (GBDP) tree based on whole-genome sequences of VL4 and other Coventryvirus members. Proteomic relationships were further analyzed with ViPtree (version 4.0)72, using TBLASTx to construct a proteome-based viral phylogenetic tree. Bacterial whole genome sequencing Genomic DNA of MRSP-HVL4 was extracted using the ZymoBiomics DNA Miniprep Kit (Zymo Research, USA) and sequenced on the Illumina HiSeq PE150 platform (Biomarker Technologies, Hong Kong). High-quality reads were de novo assembled using SPAdes v3.6.2. Gene prediction was performed with GeneMarkS-2+, and in silico multilocus sequence typing was conducted using the MLST tool from PubMLST. Prophages were identified using the PHASTEST server, while antimicrobial resistance and virulence factors were annotated through BLAST searches against the CARD and VFDB databases, respectively. Lysogeny determination To investigate the lifecycle of phage VL4, a lysogeny test was conducted based on previously protocol73,74. MRSP-HVL4 cultures were infected with VL4 and plated on LB agar, followed by incubation at 37 °C for 48 h. Individual colonies were randomly selected and screened for phage integration using PCR targeting the major capsid protein gene (ORF7) of VL4. The primers used were VL4cap-F (5′-ACCGAAAATCAACGTCAGCC-3′) and VL4cap-R (5′-ACAGACAAGTTTGCACGTCC-3′). Determination of optimal MOI The optimal MOI was determined using the method previously described75. Briefly, MRSP-HVL4 cultures in logarithmic phase (108 CFU/mL) were infected with phage VL4 at MOIs of 0.01, 0.1, 1, 10, and 100 PFU/CFU. Following 8 h incubation at 37 °C, phage titers were quantified using the double agar overlay plaque assay. Each condition was tested in triplicate to determine the MOI yielding the highest phage progeny. Adsorption and one-step growth curve assay Phage adsorption was assessed as previously described28,76, with minor modifications. Log-phase MRSP-HVL4 cultures (~ 108 CFU/mL) were mixed with phage VL4 at an MOI of 0.01 and incubated at 37 °C. At designated time points (0, 2, 4, 6, 8, 10, 15, and 20 min), aliquots were withdrawn, filtered through 0.45 μm membranes, and the number of unadsorbed phages was determined using the double agar overlay plaque assay. A one-step growth curve assay was conducted to determine the latent period and burst size of VL4, following a previously described protocol77. MRSP-HVL4 was infected with VL4 at an MOI of 0.01 and incubated for 10 min at 37 °C to allow adsorption. The mixture was then centrifuged to remove unbound phages, and the pellet was resuspended in fresh LB broth and incubated at 37 °C with shaking (120 rpm). Samples were collected every 10 min over 120 min, and phage titers were quantified by the double agar overlay plaque assay. All experiments were performed in triplicate. Phage host range, EOP, and bacteriolytic activity The host range of phage VL4 was first assessed by spotting 20 µL of a high-titer phage suspension (109 PFU/mL) onto bacterial lawns of the strains listed in Table 1. Plates were incubated at 37 °C overnight, and lytic activity was evaluated by the presence of clear zones. Phage diluent (SM buffer) was used as a negative control to confirm that no clearing occurred in the absence of phage. Positive results from spot testing were subsequently verified by a double-agar overlay plaque assay to confirm productive infection. The EOP was determined based on plaque formation. Phage suspensions were serially diluted ten-fold, and 100 µL of each dilution was mixed with 100 µL of an overnight bacterial culture. The mixture was added to 3 mL of molten soft agar and overlaid onto LB agar plates. After overnight incubation at 37 °C, plaques were enumerated and used to calculate EOP values by comparing the plaque counts on each susceptible strain to those obtained with the reference host MRSP-HVL4. EOP values were categorized as follows: high (0.5–1.0), medium (0.2–0.5), low (0.001–0.2), and ineffective (< 0.001)78. For bacteriolytic activity, log-phase of S. pseudintermedius strains (MRSP-HVL4, MRSP-BA04, MRSP-BA05, and MSSP-BA28) cultures (~ 108 CFU/mL) were infected with freshly prepared suspensions of phage VL4 at MOIs of 0.1, and 1. The absorbance at OD600 was measured every 30 min for 16 h using a microplate reader (Molecular Devices, USA). All assays were performed in triplicate. Thermal and pH stability testing Freshly prepared suspensions of phage VL4 (108 PFU/mL) in SM buffer were used for both thermal and pH stability assays. For thermal stability, phage VL4 (108 PFU/mL) in SM buffer were incubated at 4 °C, 25 °C, 37 °C, 40 °C, 50 °C, 60 °C, and 70 °C for 1 h. Phage titers were then determined using the double agar overlay plaque assay. For pH stability, VL4 suspensions (108 PFU/mL) were incubated at 37 °C for 1 h in SM buffer adjusted to pH values ranging from 1.0 to 10.0. Phage viability was assessed by double agar overlay plaque assay. All experiments were conducted in triplicate. Biofilm formation, and phage-mediated biofilm inhibition and degradation assays Biofilm formation by clinical isolates of S. pseudintermedius was assessed using a crystal violet assay as described previously79. Overnight cultures of each strain were adjusted to a 0.5 McFarland standard in in tryptic soy broth (TSB) supplemented with 1% D-glucose and dispensed into flat bottom polystyrene microtiter plates. The plates were incubated at 37 °C for 24 h under static conditions. Sterile TSB with 1% D-glucose served as the negative control, and S. aureus ATCC 43300 was included as the positive control ((biofilm producer). After incubation, medium was gently removed to avoid disturbing the biofilm, followed by rinsing with phosphate-buffered saline (PBS; pH 7.2). The wells were then fixed with absolute ethanol for 15 min and stained with crystal violet for 15 min. Excess dye was washed off with distilled water, and the bound stain was solubilized with 33% acetic acid. The OD was measured at 570 nm using a microplate reader to determine the total biomass. Biofilm formation in clinical isolates was classified according to previously described criteria80, based on the cut-off optical density (ODc). The ODc was calculated as the mean OD of the negative control plus three standard deviations (ODc = mean OD of negative control + 3 × SD). Strains were categorized as follows: non-biofilm producers (OD ≤ ODc), weak biofilm producers (ODc < OD ≤ 2 × ODc), moderate biofilm producers (2 × ODc < OD ≤ 4 × ODc), and strong biofilm producers (OD > 4 × ODc). For phage-mediated biofilm inhibition, overnight cultures of S. pseudintermedius strains MRSP-HVL4, MRSP-BA04, MRSP-BA05, and MSSP-BA28 were adjusted to approximately 1 × 108 CFU/mL in TSB supplemented with 1% D-glucose. A 250 µL aliquot was dispensed into each well of a 48-well microtiter plate, and freshly prepared suspensions of phage VL4 was added to final concentrations of 107, 108, or 109 PFU/mL. Wells without phage served as controls. Plates were incubated statically at 37 °C for 24 h, washed twice with PBS to remove non-adherent cells, and biofilm quantification was carried out as described above. For biofilm degradation assays, 24-h-old pre-formed biofilms of the same strains were prepared under identical conditions. After PBS washing to remove planktonic cells, 500 µL of freshly phage VL4 at 108, 109, or 1010 PFU/mL was added, and plates were incubated at 37 °C for 24 h. The total biomass was determined as mentioned above. The percentage of biofilm formation was determined from OD measurements obtained using the crystal violet assay. % Biofilm formation = (ODsample / ODcontrol × 100, where ODsample represents the OD of the phage-treated sample, and ODcontrol represents that of the untreated bacterial culture (without phage treatment). To determine viable cell counts within the biofilm, adherent cells were scraped from the plate surface and resuspended in PBS. The suspension was serially diluted and spread on LB agar plates, followed by incubation at 37 °C for 24 h. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The authors would like to thank Mr. Thassanant Atithep from the Frontier Research Center, Vidyasirimedhi Institute of Science and Technology, Rayong, Thailand, for his valuable support and technical assistance with TEM imaging. Author contributions PW: Data analysis, Data curation, Writing original draft, Writing review and editing. SA and PS: Investigation, Writing review and editing. NP: Resources, Data curation, Writing review and editing. VL: Conceptualization, Methodology, Investigation, Data curation, Visualization, Writing original draft, Writing review and editing, Supervision, Funding acquisition. Funding This research project was supported by the Faculty of Veterinary Science, Mahidol University, Thailand. Data availability The complete genomic sequence of phage VL4 has been submitted to the GenBank database under the accession number OP168678.1. Additionally, the whole genome sequencing data for the bacterial propagating strain MRSP HVL4 has been recorded under the GenBank WGS project with the Bioproject PRJNA1150973, biosample accession SAMN43299076 and the accession number JBGOQL000000000. All datasets are now publicly accessible. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The complete genomic sequence of phage VL4 has been submitted to the GenBank database under the accession number OP168678.1. Additionally, the whole genome sequencing data for the bacterial propagating strain MRSP HVL4 has been recorded under the GenBank WGS project with the Bioproject PRJNA1150973, biosample accession SAMN43299076 and the accession number JBGOQL000000000. All datasets are now publicly accessible.